CliffBio
biologic

Opdivo Qvantig

nivolumab and hyaluronidase-nvhy

Loss of exclusivityDecember 2036projected — 12-year biologic exclusivity estimate
CompanyBristol-Myers Squibb Company →See this company's full patent-cliff portfolio

Drug detail

Brand nameOpdivo Qvantig
Active ingredientnivolumab and hyaluronidase-nvhy
Strength600MG/5ML;10,000UNITS/5ML (120MG/2,000UNITS/ML)
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalDecember 2024
Marketing statusRx

More from Bristol-Myers Squibb Company

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Opdivo Qvantig patent cliff — loss of exclusivity December 2036 | CliffBio